BBIO Q3 2025 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$121M+4318.0% YoY

Gross Profit

$114M94.6% margin

Operating Income

-$145M-120.3% margin

Net Income

-$183M-151.4% margin

EPS (Diluted)

$-0.96

QoQ Revenue Growth

+9.2%

Cash Flow

Operating Cash Flow

-$110M

Free Cash Flow

-$110M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$998M

Total Liabilities

$2.9B

Stockholders' Equity

-$1.9B

Cash & Equivalents

$643M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$121M	$3M	+4318.0%
Gross Profit	$114M	$2M	+5248.5%
Operating Income	-$145M	-$192M	+24.3%
Net Income	-$183M	-$162M	-12.8%

Revenue Segments

Product

$108M90%

License and Service

$8M7%

Royalty

$4M4%